Abstract
Chronic dialysis and renal transplantation are both very good treatments for end-stage renal disease (ESRD). The majority of adults with ESRD are receiving dialysis rather than undergoing renal transplantation. The number of adults seeking renal transplantation is rising, but the number performed has been limited by the lack of appropriate donors [1]. There is a survival advantage of transplantation for virtually all candidates [2]. Renal transplantation was recognized as the better form of treatment for children with ESRD almost three decades ago [3] and has repeatedly shown to provide a survival benefit for children [4, 5]. Both peritoneal dialysis, delivered as CAPD or CCPD, and hemodialysis provide a worse quality of life, unsatisfactory growth rate, as well as ongoing complications as compared to renal transplantation. Data from the dialysis component of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry [6] show that the overall height deficit of −1.8 S.D. became more negative reaching a value of −2.16 S.D. at 24 months after initiation of dialysis. Additionally children do not tolerate being “dependent” on any modality, and maintenance dialysis induces loss of self-esteem and emotional maladjustment [7]. Cognitive achievement testing may diminish with prolonged time on dialysis [8]. In contrast, the mobility and freedom from dietary restrictions afforded by a functioning renal transplant enable children to live nearly normal lives. Renal transplantation has not lived up to the promise of normal growth for all children, but dramatic short-term improvements in height can be seen in many and final adult height is improving after transplantation [9–13]. Importantly, successful transplantation permits the child to attend school and to develop normally, and school function testing improves dramatically following transplantation [14, 15]. Importantly, young children have the best long-term outcomes of all age groups of transplant recipients, verifying the utility of transplantation in this age group [16–18]. For all of these reasons, successful renal transplantation remains the primary goal of programs that care for children with ESRD [5, 19]. Pediatric recipients of kidney transplants have high percentages of living donors, and they receive substantial preference on the deceased-donor transplant waiting list in many countries [20, 21], leading to potentially short waiting times [22]. Thus, pediatric patients with ESRD should not have substantial delays in undergoing renal transplantation after they develop ESRD, although the goal of rapid progression to kidney transplantation has not been universally achieved [23].
This is a preview of subscription content, log in via an institution to check access.
References
Gaston RS, Danovitch GM, Adams PL, Wynn JJ, Merion RM, Deierhoi MH, Metzger RA, Cecka JM, Harmon WE, Leichtman AB, Spital A, Blumberg E, Herzog CA, Wolfe RA, Tyan DB, Roberts J, Rohrer R, Port FK, Delmonico FL. The report of a national conference on the wait list for kidney transplantation. Am J Transplant. 2003;3(7):775–85.
Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surgery. 2015;150(3):252–9.
Fine RN. Renal transplantation for children-the only realistic choice. Kidney Int Suppl. 1985;17(7):S15–7.
Gillen DL, Stehman-Breen CO, Smith JM, McDonald RA, Warady BA, Brandt JR, Wong CS. Survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation. Am J Transplant. 2008;8(12):2600–6.
Smith JM, Martz K, Blydt-Hansen TD. Pediatric kidney transplant practice patterns and outcome benchmarks, 1987–2010: A report of the North American pediatric renal trials and collaborative studies. Pediatr Transplant. 2013;17(2):149–57.
Warady BA, Hebert D, Sullivan EK, Alexander SR, Tejani A. Renal transplantation, chronic dialysis, and chronic renal insufficiency in children and adolescents. The 1995 annual report of the North American pediatric renal transplant cooperative study. Pediatr Nephrol. 1997;11(1):49–64.
Trachtman H, Hackney P, Tejani A. Pediatric hemodialysis: a decade’s (1974–1984) perspective. Kidney Int Suppl. 1986;19(22):S15–22.
Brouhard BH, Donaldson LA, Lawry KW, McGowan KR, Drotar D, Davis I, Rose S, Cohn RA, Tejani A. Cognitive functioning in children on dialysis and post-transplantation. Pediatr Transplant. 2000;4(4):261–7.
Fine RN. Growth following solid-organ transplantation. Pediatr Transplant. 2002;6(1):47–52.
Fine RN, Ho M, Tejani A, S. North American Pediatric Renal Transplant Cooperative. The contribution of renal transplantation to final adult height: a report of the North American pediatric renal transplant cooperative study (NAPRTCS). Pediatr Nephrol. 2001;16(12):951–6.
Fine RN, Martz K, Stablein D. What have 20 years of data from the North American pediatric renal transplant cooperative study taught us about growth following renal transplantation in infants, children, and adolescents with end-stage renal disease? Pediatr Nephrol. 2010;25(4):739–46.
Ingelfinger JR, Grupe WE, Harmon WE, Fernbach SK, Levey RH. Growth acceleration following renal transplantation in children less than 7 years of age. Pediatrics. 1981;68(2):255–9.
Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra Jr O. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation. 2001;72(1):13–21.
Fennell EB, Fennell RS, Mings E, Morris MK. The effects of various modes of therapy for end stage renal disease on cognitive performance in a pediatric population–a preliminary report. Int J Pediatr Nephrol. 1986;7(2):107–12.
Mendley SR, Zelko FA. Improvement in specific aspects of neurocognitive performance in children after renal transplantation. Kidney Int. 1999;56(1):318–23.
Colombani PM, Dunn SP, Harmon WE, Magee JC, McDiarmid SV, Spray TL. Pediatric Transplantation. Am J Transplant. 2003;3 Suppl 4:53–63.
Magee JC, Krishnan SM, Benfield MR, Hsu DT, Shneider BL. Pediatric transplantation in the United States, 1997–2006. Am J Transplant. 2008;8(4 Pt 2):935–45.
Dharnidharka VR, Fiorina P, Harmon WE. Kidney transplantation in children. N Engl J Med. 2014;371(6):549–58.
Moudgil A, Martz K, Stablein DM, Puliyanda DP. Good outcome of kidney transplants in recipients of young donors: a NAPRTCS data analysis. Pediatr Transplant. 2011;15(2):167–71.
Gritsch HA, Veale JL, Leichtman AB, Guidinger MK, Magee JC, McDonald RA, Harmon WE, Delmonico FL, Ettenger RB, Cecka JM. Should pediatric patients wait for HLA-DR-matched renal transplants? Am J Transplant. 2008;8(10):2056–61.
Moudgil A, Dharnidharka VR, Lamb KE, Meier-Kriesche HU. Best allograft survival from share-35 kidney donors occurs in middle-aged adults and young children-an analysis of OPTN data. Transplantation. 2013;95(2):319–25.
Reese PP, Hwang H, Potluri V, Abt PL, Shults J, Amaral S. Geographic determinants of access to pediatric deceased donor kidney transplantation. J Am Soc Nephrol. 2014;25(4):827–35.
Nguyen S, Martz K, Stablein D, Neu A. Wait list status of pediatric dialysis patients in North America. Pediatr Transplant. 2011;15(4):376–83.
Matas AJ, Smith JM, Skeans MA, Lamb KE, Gustafson SK, Samana CJ, Stewart DE, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011 annual data report: kidney. Am J Transplant. 2013;13 Suppl 1:11–46.
Dale-Shall AW, Smith JM, McBride MA, Hingorani SR, McDonald RA. The relationship of donor source and age on short- and long-term allograft survival in pediatric renal transplantation. Pediatr Transplant. 2009;13(6):711–8.
Cecka JM, Gjertson DW, Terasaki PI. Pediatric renal transplantation: a review of the UNOS data. Pediatr Transplant. 1997;1(1):55–64.
Neu AM, Stablein DM, Zachary A, Furth SL, Fivush BA. Effect of parental donor sex on rejection in pediatric renal transplantation: a report of the North American pediatric renal transplant cooperative study. Pediatr Transplant. 1998;2(4):309–12.
Price DP. Minors as living donors: ethics and law. Transplant Proc. 1996;28(6):3607–8.
Spital A. Should children ever donate kidneys? Views of U.S. transplant centers. Transplantation. 1997;64(2):232–6.
Delmonico FL, Harmon WE. The use of a minor as a live kidney donor.[see comment]. Am J Transplant. 2002;2(4):333–6.
Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors [see comments]. N Engl J Med. 1995;333(6):333–6.
Al-Uzri A, Sullivan EK, Fine RN, Harmon WE. Living-unrelated renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) [see comment]. Pediatr Transplant. 1998;2(2):139–44.
Davies DB, Breen TJ, Guo T, Ellison MD, Daily OP, Harmon WE. Waiting times to pediatric transplantation: an assessment of the August 1990 change in renal allocation policy. Transplant Proc. 1994;26(1):30–1.
McEnery PT, Alexander SR, Sullivan K, Tejani A. Renal transplantation in children and adolescents: the 1992 annual report of the North American pediatric renal transplant cooperative study. Pediatr Nephrol. 1993;7(6):711–20.
Tejani A, Sullivan EK, Fine RN, Harmon W, Alexander S. Steady improvement in renal allograft survival among North American children: a five year appraisal by the North American pediatric renal transplant cooperative study. Kidney Int. 1995;48(2):551–3.
Feld LG, Stablein D, Fivush B, Harmon W, Tejani A. Renal transplantation in children from 1987–1996: the 1996 annual report of the North American pediatric renal transplant cooperative study. Pediatr Transplant. 1997;1(2):146–62.
Butani L, Troppmann C, Perez RV. Outcomes of children receiving en bloc renal transplants from small pediatric donors. Pediatr Transplant. 2013;17(1):55–8.
Filler G, Lindeke A, Bohme K, Devaux S, Schonberger B, Ehrich JHH. Renal transplantation from donors aged <6 years into children yields equal graft survival when compared to older donors. Pediatr Transplant. 1997;1:119–23.
Hiramoto JS, Freise CE, Randall HR, Bretan PN, Tomlanovich S, Stock PG, Hirose R. Successful long-term outcomes using pediatric en bloc kidneys for transplantation. Am J Transplant. 2002;2(4):337–42.
Kayler LK, Zendejas I, Gregg A, Wen X. Kidney transplantation from small pediatric donors: does recipient body mass index matter? Transplantation. 2012;93(4):430–6.
Ettenger RB. Age and the immune response in pediatric renal transplantation. Eur J Pediatr. 1992;151 Suppl 1:S7–8.
Ettenger RB, Blifeld C, Prince H, Gradus DB, Cho S, Sekiya N, Salusky IB, Fine RN. The pediatric nephrologist’s dilemma: growth after renal transplantation and its interaction with age as a possible immunologic variable. J Pediatr. 1987;111(6 Pt 2):1022–5.
Briscoe DM, Kim MS, Lillehei C, Eraklis AJ, Levey RH, Harmon WE. Outcome of renal transplantation in children less than two years of age. Kidney Int. 1992;42(3):657–62.
Najarian JS, Frey DJ, Matas AJ, Gillingham KJ, So SS, Cook M, Chavers B, Mauer SM, Nevins TE. Renal transplantation in infants. Ann Surg. 1990;212(3):353–65.
Ingulli E, Matas AJ, Nevins TE, Kashtan CE, Mauer SM, Gillingham K, Chavers BM. Impact of age on renal graft survival in children after the first rejection episode. Pediatr Nephrol. 1996;10(4):474–8.
Scomik JC, Cecka M. Clinical parameters of immune responsiveness in children and African American transplant patients. 16th Annual Meeting of the American Society of Transplant Physicians, Chicago, Abs. 1997.
Strehlau J, Sharma VK, Pavalakis M, Schachter A, Ding R, Shapiro M, Harmon W, Benfield M, Tejani A, Suthanthiran M, Strom T. Do children have a heightened immune response to acute allograft rejection? A preliminary comparative study of intragraft gene transcripts of immune activation markers in adult and pediatric graft rejection. 16th annual meeting of the American society of transplant physicians, Chicago, Abstract. 1997.
Chavers BM, Gillingham KJ, Matas AJ. Complications by age in primary pediatric renal transplant recipients. Pediatr Nephrol. 1997;11(4):399–403.
Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL. Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol. 1991;5(1):1–4.
Lemire J, Capparelli EV, Benador N, Grimm P, Macdonald D, Reznik V. Neoral pharmacokinetics in Latino and Caucasian pediatric renal transplant recipients. Pediatr Nephrol. 2001;16(4):311–4.
Schachter A, Spaneas L, Palmer J, Meyers K, Brayman K, Harmon W. Sirolimus half life in pediatric renal transplant recipients not receiving calcineurin inhibitors is very short (Abs). Am J Transplant. 2002;2 Suppl 3:255.
Harmon WE, McDonald RA, Reyes JD, Bridges ND, Sweet SC, Sommers CM, Guidinger MK. Pediatric transplantation, 1994–2003. Am J Transplant. 2005;5(4 Pt 2):887–903.
Smith JM, Stablein DM, Munoz R, Hebert D, McDonald RA. Contributions of the transplant registry: The 2006 annual report of the North American pediatric renal trials and collaborative studies (NAPRTCS). Pediatr Transplant. 2007;11(4):366–73.
Furth SL, Garg PP, Neu AM, Hwang W, Fivush BA, Powe NR. Racial differences in access to the kidney transplant waiting list for children and adolescents with end-stage renal disease. Pediatrics. 2000;106(4):756–61.
Amaral S, Patzer RE, Kutner N, McClellan W. Racial disparities in access to pediatric kidney transplantation since share 35. J Am Soc Nephrol. 2012;23(6):1069–77.
Omoloja A, Mitsnefes M, Talley L, Benfield M, Neu A. Racial differences in graft survival: a report from the North American pediatric renal trials and collaborative studies (NAPRTCS). Clin J Am Soc Nephrol. 2007;2(3):524–8.
NAPRTCS. 2010 annual report. http://spitfire.emmes.com/study/ped/annlrept/2010_Report.pdf. 2010.
NAPRTCS. 2011 annual report. http://spitfire.emmes.com/study/ped/annlrept/annualrept2011.pdf. 2011.
Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS. National kidney foundation’s kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111(6 Pt 1):1416–21.
Warady BA, Abraham AG, Schwartz GJ, Wong CS, Munoz A, Betoko A, Mitsnefes M, Kaskel F, Greenbaum LA, Mak RH, Flynn J, Moxey-Mims MM, Furth S. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) cohort. Am J Kidney Dis. 2015;65(6):878–88.
Zhong Y, Munoz A, Schwartz GJ, Warady BA, Furth SL, Abraham AG. Nonlinear trajectory of GFR in children before RRT. J Am Soc Nephrol. 2014;25(5):913–7.
Ambrogi V, Thilly N, Boini S, Virion JM, Kessler M, Briancon S, Frimat L. Patterns and predictors of kidney function decline in the last year prior to dialysis. Nephron Clin Pract. 2009;111(2):c95–101.
McDonald SP, Craig JC, Australian and A. New Zealand Paediatric Nephrology. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350(26):2654–62.
Coppes MJ, de Kraker J, van Dijken PJ, Perry HJ, Delemarre JF, Tournade MF, Lemerle J, Voute PA. Bilateral Wilms’ tumor: long-term survival and some epidemiological features. J Clin Oncol. 1989;7(3):310–5.
Ritchey ML, Green DM, Thomas PR, Smith GR, Haase G, Shochat S, Moksness J, Breslow NE. Renal failure in Wilms’ tumor patients: a report from the National Wilms’ tumor study group. Med Pediatr Oncol. 1996;26(2):75–80.
Breslow NE, Collins AJ, Ritchey ML, Grigoriev YA, Peterson SM, Green DM. End stage renal disease in patients with Wilms tumor: results from the National Wilms tumor study group and the United States renal data system. J Urol. 2005;174(5):1972–5.
Breslow NE, Norris R, Norkool PA, Kang T, Beckwith JB, Perlman EJ, Ritchey ML, Green DM, Nichols KE, G. National Wilms Tumor Study. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms tumor study group. J Clin Oncol. 2003;21(24):4579–85.
Kist-van Holthe JE, Ho PL, Stablein D, Harmon WE, Baum MA. Outcome of renal transplantation for Wilms’ tumor and Denys-Drash syndrome: a report of the North American pediatric renal transplant cooperative study. Pediatr Transplant. 2005;9(3):305–10.
Grigoriev Y, Lange J, Peterson SM, Takashima JR, Ritchey ML, Ko D, Feusner JH, Shamberger RC, Green DM, Breslow NE. Treatments and outcomes for end-stage renal disease following Wilms tumor. Pediatr Nephrol. 2012;27(8):1325–33.
DeMaria JE, Hardy BE, Brezinski A, Churchill BM. Renal transplantation in patients with bilateral Wilm’s tumor. J Pediatr Surg. 1979;14(5):577–9.
Penn I. Renal transplantation for Wilms tumor: report of 20 cases. J Urol. 1979;122(6):793–4.
Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation. 1998;65(9):1187–91.
Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004–14.
El Sayegh S, Keller MJ, Huprikar S, Murphy B. Solid organ transplantation in HIV-infected recipients. Pediatr Transplant. 2004;8(3):214–21.
Shroff RC, McCulloch M, Novelli V, Shingadia D, Bradley S, Clapson M, Mamode N, Marks SD. Successful outcome of renal transplantation in a child with HIV-associated nephropathy. Arch Dis Child. 2014;99(11):1026–8.
Kasiske BL, Ramos EL, Gaston RS, Bia MJ, Danovitch GM, Bowen PA, Lundin PA, Murphy KJ. The evaluation of renal transplant candidates: clinical practice guidelines. Patient care and education committee of the American society of transplant physicians. J Am Soc Nephrol. 1995;6(1):1–34.
Richards CT, Crawley LM, Magnus D. Use of neurodevelopmental delay in pediatric solid organ transplant listing decisions: inconsistencies in standards across major pediatric transplant centers. Pediatr Transplant. 2009;13(7):843–50.
Wightman A, Young B, Bradford M, Dick A, Healey P, McDonald R, Smith J. Prevalence and outcomes of renal transplantation in children with intellectual disability. Pediatr Transplant. 2014.
Martens MA, Jones L, Reiss S. Organ transplantation, organ donation and mental retardation. Pediatr Transplant. 2006;10(6):658–64.
Ohta T, Motoyama O, Takahashi K, Hattori M, Shishido S, Wada N, Gotoh Y, Yanagihara T, Hasegawa A, Sakano T. Kidney transplantation in pediatric recipients with mental retardation: clinical results of a multicenter experience in Japan. Am J Kidney Dis. 2006;47(3):518–27.
Harmon WE, Alexander SR, Tejani A, Stablein D. The effect of donor age on graft survival in pediatric cadaver renal transplant recipients–a report of the North American pediatric renal transplant cooperative study. Transplantation. 1992;54(2):232–7.
Singh A, Stablein D, Tejani A. Risk factors for vascular thrombosis in pediatric renal transplantation: a special report of the North American pediatric renal transplant cooperative study. Transplantation. 1997;63(9):1263–7.
Sarwal MM, Cecka JM, Millan MT, Salvatierra Jr O. Adult-size kidneys without acute tubular necrosis provide exceedingly superior long-term graft outcomes for infants and small children: a single center and UNOS analysis. United network for organ sharing. Transplantation. 2000;70(12):1728–36.
Ghane Sharbaf F, Bitzan M, Szymanski KM, Bell LE, Gupta I, Tchervenkov J, Capolicchio JP. Native nephrectomy prior to pediatric kidney transplantation: biological and clinical aspects. Pediatr Nephrol. 2012;27(7):1179–88.
Salvatierra Jr O, Sarwal M. Renal perfusion in infant recipients of adult-sized kidneys is a critical risk factor. Transplantation. 2000;70(3):412–3.
Fasola CG, Gillingham KJ, Troppmann C, Gruessner RW, Gores PF, Dunn DL, Payne WD, Sutherland DE, Matas AJ, Najarian JS. Kidney transplant or retransplant can effectively treat congenital nephrotic syndrome: a single-center experience. Transplant Proc. 1994;26(1):9.
Holmberg C, Jalanko H, Koskimies O, Leijala M, Salmela K, Eklund B, Ahonen J. Renal transplantation in small children with congenital nephrotic syndrome of the Finnish type. Transplant Proc. 1991;23(1 Pt 2):1378–9.
Kim MS, Primack W, Harmon WE. Congenital nephrotic syndrome: preemptive bilateral nephrectomy and dialysis before renal transplantation. J Am Soc Nephrol. 1992;3(2):260–3.
Fine RN. Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective. Pediatr Nephrol. 2010;25(4):725–32.
Chaves TS, Pereira LM, De Santos SS, David-Neto E, Lopes MH. Evaluation of the vaccination status in pediatric renal transplant recipients. Pediatr Transplant. 2008;12(4):432–5.
Furth SL, Fivush BA. Varicella vaccination in pediatric kidney transplant candidates. Pediatr Transplant. 2002;6(2):97–100.
Laube GF, Berger C, Goetschel P, Leumann E, Neuhaus TJ. Immunization in children with chronic renal failure. Pediatr Nephrol. 2002;17(8):638–42.
Olson AD, Shope TC, Flynn JT. Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. Pediatr Transplant. 2001;5(1):44–50.
Churchill BM, Sheldon CA, McLorie GA, Arbus GS. Factors influencing patient and graft survival in 300 cadaveric pediatric renal transplants. J Urol. 1988;140(5 Pt 2):1129–33.
Rudge CJ. Transplantation and the abnormal bladder. In: Morris PJ, editor. Kidney transplantation: principles and practice. Philadelphia: WB Saunders; 1994. p. 138–48.
Salvatierra O, Tanney D, Mak R, Alfrey E, Lemley K, Mackie F, So S, Hammer GB, Krane EJ, Conley SB. Pediatric renal transplantation and its challenges. Transplant Rev. 1997;11:51–69.
Koo HP, Bunchman TE, Flynn JT, Punch JD, Schwartz AC, Bloom DA. Renal transplantation in children with severe lower urinary tract dysfunction.[comment]. Journal of Urology. 1999;161(1):240–5.
Nahas WC, Mazzucchi E, Arap MA, Antonopoulos IM, Neto ED, Ianhez LE, Arap S. Augmentation cystoplasty in renal transplantation: a good and safe option–experience with 25 cases. Urology. 2002;60(5):770–4.
Power RE, O’Malley KJ, Khan MS, Murphy DM, Hickey DP. Renal transplantation in patients with an augmentation cystoplasty. BJU Int. 2000;86(1):28–31.
Alam S, Sheldon C. Urological issues in pediatric renal transplantation. Curr Opin Urol. 2008;18(4):413–8.
Capizzi A, Zanon GF, Zacchello G, Rigamonti W. Kidney transplantation in children with reconstructed bladder. Transplantation. 2004;77(7):1113–6.
DeFoor W, Minevich E, McEnery P, Tackett L, Reeves D, Sheldon C. Lower urinary tract reconstruction is safe and effective in children with end stage renal disease. Journal of Urology. 2003;170(4 Pt 2):1497–500. discussion 1500.
DeFoor W, Tackett L, Minevich E, McEnery P, Kitchens D, Reeves D, Sheldon C. Successful renal transplantation in children with posterior urethral valves. Journal of Urology. 2003;170(6 Pt 1):2402–4.
Djakovic N, Wagener N, Adams J, Gilfrich C, Haferkamp A, Pfitzenmaier J, Toenshoff B, Schmidt J, Hohenfellner M. Intestinal reconstruction of the lower urinary tract as a prerequisite for renal transplantation. BJU Int. 2009;103(11):1555–60.
Franc-Guimond J, Gonzalez R. Renal transplantation in children with reconstructed bladders. Transplantation. 2004;77(7):1116–20.
Otukesh H, Basiri A, Simfroosh N, Hoseini R, Fereshtehnejad SM, Chalian M. Kidney transplantation in children with posterior urethral valves. Pediatr Transplant. 2008;12(5):516–9.
Pereira DA, Barroso Jr U, Machado P, Pestana JO, Rosito TE, Pires J, Almeida C, Ortiz V, Macedo Jr A. Effects of urinary tract infection in patients with bladder augmentation and kidney transplantation. J Urol. 2008;180(6):2607–10. discussion 2610.
Basiri A, Otookesh H, Hosseini R, Simforoosh N, Moghaddam SM. Kidney transplantation before or after augmentation cystoplasty in children with high-pressure neurogenic bladder. BJU Int. 2009;103(1):86–8. discussion 88.
Broyer M. What are the indications for nephrectomy, either bilateral or unilateral, prior to transplantation in children? Pediatr Nephrol. 1991;5(1):11.
Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, Stewart DE, Cherikh WS, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2012 annual data report: kidney. Am J Transplant. 2014;14 Suppl 1:11–44.
Tait BD, Susal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II SV, Fuggle J, Gill D, Glotz N, Lachmann T, Mohanakumar N, Suciu-Foca S, Sumitran-Holgersson K, Tanabe CJ, Taylor DB, Tyan A, Webster AZ, Opelz G. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95(1):19–47.
van den Berg-Loonen EM, Billen EV, Voorter CE, van Heurn LW, Claas FH, van Hooff JP, Christiaans MH. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation. 2008;85(8):1086–90.
Bohmig GA. Impact of live-donor exchange on transplant waiting time. Transpl Int. 2012;25(10):1024–5.
de Klerk M, Weimar W. Ingredients for a successful living donor kidney exchange program. Transplantation. 2008;86(4):511–2.
de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Claas FH, Weimar W. A highly efficient living donor kidney exchange program for both blood type and crossmatch incompatible donor-recipient combinations. Transplantation. 2006;82(12):1616–20.
de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Claas FH, Weimar W. Hurdles, barriers, and successes of a national living donor kidney exchange program. Transplantation. 2008;86(12):1749–53.
Delmonico FL, Morrissey PE, Lipkowitz GS, Harmon W, Himmelfarb J, Stoff J, Pavlakis M, Mah H, Goguen J, Luskin R, Milford E, Rohrer RJ. Donor kidney exchange for incompatible donors. Am J Transplant. 2003;3 Suppl 5:550.
Den Hartogh G. Trading with the waiting-list: the justice of living donor list exchange. Bioethics. 2010;24(4):190–8.
Hanto RL, Reitsma W, Delmonico FL. The development of a successful multiregional kidney paired donation program. Transplantation. 2008;86(12):1744–8.
Huh KH, Kim MS, Ju MK, Chang HK, Ahn HJ, Lee SH, Lee JH, Kim SI, Kim YS, Park K. Exchange living-donor kidney transplantation: merits and limitations. Transplantation. 2008;86(3):430–5.
Kim BS, Kim YS, Kim SI, Kim MS, Lee HY, Kim YL, Kim CD, Yang CW, Choi BS, Han DJ, Kim SJ, Oh HY, Kim DJ. Outcome of multipair donor kidney exchange by a web-based algorithm. J Am Soc Nephrol. 2007;18(3):1000–6.
Montgomery RA, Lonze BE, Jackson AM. Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients. Curr Opin Organ Transplant. 2011;16(4):439–43.
Spital A. Increasing the pool of transplantable kidneys through unrelated living donors and living donor paired exchanges. Semin Dial. 2005;18(6):469–73.
Waterman AD, Schenk EA, Barrett AC, Waterman BM, Rodrigue JR, Woodle ES, Shenoy S, Jendrisak M, Schnitzler M. Incompatible kidney donor candidates’ willingness to participate in donor-exchange and non-directed donation. Am J Transplant. 2006;6(7):1631–8.
Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;2(8):758–60.
Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15(12):3256–62.
Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242–51.
Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Nyberg SL, Larson TS, Griffin MD, Textor SC, Velosa JA, Schwab TR, Fix LA, Stegall MD. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant. 2003;3(8):1017–23.
Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70(6):887–95.
Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6(2):346–51.
Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365(4):318–26.
Seikaly M, Ho PL, Emmett L, Tejani A. The 12th annual report of the North American pediatric renal transplant cooperative study: renal transplantation from 1987 through 1998 (updated at http://www.naprtcs.org). Pediatr Transplant. 2001;5(3):215–31.
Baum MA, Stablein DM, Panzarino VM, Tejani A, Harmon WE, Alexander SR. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int. 2001;59(1):328–33.
Cochat P, Fargue S, Mestrallet G, Jungraithmayr T, Koch-Nogueira P, Ranchin B, Zimmerhackl LB. Disease recurrence in paediatric renal transplantation. Pediatr Nephrol. 2009;24(11):2097–108.
Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant. 2008;12(6):619–29.
Delmonico FL, Harmon WE. Pediatric kidney transplantation in the United States: the current realities. Am J Transplant. 2008;8(12):2487–8.
Harmon WE, Stablein D, Alexander SR, Tejani A. Graft thrombosis in pediatric renal transplant recipients. A report of the North American pediatric renal transplant cooperative study. Transplantation. 1991;51(2):406–12.
Horslen S, Barr ML, Christensen LL, Ettenger R, Magee JC. Pediatric transplantation in the United States, 1996–2005. Am J Transplant. 2007;7 Suppl 1:1339–58.
Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, Gross CR, Matas AJ. Long-term consequences of kidney donation. N Engl J Med. 2009;360(5):459–69.
Delmonico F, S. Council of the Transplantation. A report of the Amsterdam forum on the care of the live kidney donor: data and medical guidelines. Transplantation. 2005;79 Suppl 6:S53–66.
Joseph JW, Thistlethwaite Jr JR, Josephson MA, Ross LF. An empirical investigation of physicians’ attitudes toward intrasibling kidney donation by minor twins. Transplantation. 2008;85(9):1235–9.
Ahmad N, Ahmed K, Khan MS, Calder F, Mamode N, Taylor J, Koffman G. Living-unrelated donor renal transplantation: an alternative to living-related donor transplantation? Ann R Coll Surg Engl. 2008;90(3):247–50.
Cecka JM. The OPTN/UNOS renal transplant registry. Clin Transpl. 2005;1–16.
Gheith O, Sabry A, El-Baset SA, Hassan N, Sheashaa H, Bahgat S, El-Shahawy E-M, Study of the effect of donor source on graft and patient survival in pediatric renal transplant recipients. Pediatr Nephrol. 2008;23(11):2075–9.
Jacobs CL, Roman D, Garvey C, Kahn J, Matas AJ. Twenty-two nondirected kidney donors: an update on a single center’s experience. Am J Transplant. 2004;4(7):1110–6.
Kaneku HK, Terasaki PI. Thirty year trend in kidney transplants: UCLA and UNOS renal transplant registry. Clin Transpl. 2006;1–27.
Morrissey PE, Dube C, Gohh R, Yango A, Gautam A, Monaco AP. Good Samaritan kidney donation. Transplantation. 2005;80(10):1369–73.
O’Connor KJ, Delmonico FL. Increasing the supply of kidneys for transplantation. Semin Dial. 2005;18(6):460–2.
Matas AJ. Should we pay donors to increase the supply of organs for transplantation? Yes. BMJ. 2008;336(7657):1342.
Matas AJ, Hippen B, Satel S. In defense of a regulated system of compensation for living donation. Curr Opin Organ Transplant. 2008;13(4):379–85.
International Summit on Transplant, T. and T. Organ. The declaration of Istanbul on organ trafficking and transplant tourism. Clin J Am Soc Nephrol. 2008;3(5):1227–31.
Steering Committee of the Istanbul, S. Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul. Lancet. 2008;372(9632):5–6.
Gentry SE, Segev DL, Simmerling M, Montgomery RA. Expanding kidney paired donation through participation by compatible pairs. Am J Transplant. 2007;7(10):2361–70.
Marks WH, Wagner D, Pearson TC, Orlowski JP, Nelson PW, McGowan JJ, Guidinger MK, Burdick J. Organ donation and utilization, 1995–2004: entering the collaborative era. Am J Transplant. 2006;6(5 Pt 2):1101–10.
Tuncer M, Tekin S, Yucetin L, Sengul A, Demirbas A. Comparison of paired exchange kidney transplantations with living related kidney transplantations. Transplant Proc. 2012;44(6):1626–7.
Bia MJ, Ramos EL, Danovitch GM, Gaston RS, Harmon WE, Leichtman AB, Lundin PA, Neylan J, Kasiske BL. Evaluation of living renal donors. The current practice of US transplant centers. Transplantation. 1995;60(4):322–7.
Davis CL. Evaluation of the living kidney donor: current perspectives. Am J Kidney Dis. 2004;43(3):508–30.
Boudville N, Prasad GV, Knoll G, Muirhead N, Thiessen-Philbrook H, Yang RC, Rosas-Arellano MP, Housawi A, Garg AX. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med. 2006;145(3):185–96.
Fehrman-Ekholm I. Living donor kidney transplantation. Transplant Proc. 2006;38(8):2637–41.
Goldfarb DA, Matin SF, Braun WE, Schreiber MJ, Mastroianni B, Papajcik D, Rolin HA, Flechner S, Goormastic M, Novick AC. Renal outcome 25 years after donor nephrectomy. J Urol. 2001;166(6):2043–7.
Schostak M, Wloch H, Muller M, Schrader M, Offermann G, Miller K. Optimizing open live-donor nephrectomy – long-term donor outcome. Clin Transplant. 2004;18(3):301–5.
Mueller TF, Luyckx VA. The natural history of residual renal function in transplant donors. J Am Soc Nephrol. 2012;23(9):1462–6.
Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, McBride MA, Montgomery RA. Perioperative mortality and long-term survival following live kidney donation. Jama. 2010;303(10):959–66.
Fonouni H, Mehrabi A, Golriz M, Zeier M, Muller-Stich BP, Schemmer P, Werner J. Comparison of the laparoscopic versus open live donor nephrectomy: an overview of surgical complications and outcome. Langenbecks Arch Surg. 2014;399(5):543–51.
Troppmann C, McBride MA, Baker TJ, Perez RV. Laparoscopic live donor nephrectomy: a risk factor for delayed function and rejection in pediatric kidney recipients? A UNOS analysis.[see comment]. Am J Transplant. 2005;5(1):175–82.
Chaykovska L, Deger S, Roigas J, Lenz A, Lioudmer P, Kothmann LT, Friedersdorff F, Muller D, Kasper A, Giessing M, Magheli A, Kempkensteffen C, Lingnau A, Fuller TF. Long-term outcomes of living donor kidney transplants in pediatric recipients following laparoscopic vs. open donor nephrectomy. Pediatr Transplant. 2012;16(8):894–900.
Choi SW, Kim KS, Kim S, Choi YS, Bae WJ, Hong SH, Lee JY, Kim SW, Hwang TK, Cho HJ. Hand-assisted and pure laparoscopic living donor nephrectomy: a matched-cohort comparison over 10 year at a single institute. Clin Transplant. 2014;28(11):1287–93.
McEnery PT, Stablein DM, Arbus G, Tejani A. Renal transplantation in children. A report of the North American pediatric renal transplant cooperative study. New England Journal of Medicine. 1992;326(26):1727–32.
Bresnahan BA, McBride MA, Cherikh WS, Hariharan S. Risk factors for renal allograft survival from pediatric cadaver donors: an analysis of united network for organ sharing data. Transplantation. 2001;72(2):256–61.
Ruff T, Reddy KS, Johnston TD, Waid T, McKeown W, Khan T, Ranjan D, Lucas BA. Transplantation of pediatric en bloc cadaver kidneys into adult recipients: a single-center experience. American Surgeon. 2002;68(10):857–9.
Takemoto S, Terasaki PI. Donor age and recipient age. Clin Transpl. 1988;345–56.
Terasaki PI, Gjertson DW, Cecka JM, Takemoto S, Cho YW. Significance of the donor age effect on kidney transplants. Clin Transplant. 1997;11(5 Pt 1):366–72.
Tejani A, Sullivan EK, Alexander SR, Harmon WE, Kohaut E, Fine RN (1998) The impact of donor source, pre-operative immunotherapy and prophylactic antibody therapy on first rejection episodes in children. Pediatr Transplant. 1998;2(4):318–24.
Toma H, Tanabe K, Tokumoto T, Shimizu T, Shimmura H. Time-dependent risk factors influencing the long-term outcome in living renal allografts: donor age is a crucial risk factor for long-term graft survival more than 5 years after transplantation. Transplantation. 2001;72(5):940–7.
Cecka JM. The UNOS scientific renal transplant registry-ten years of kidney transplants. Los Angeles: UCLA; 1997.
Cho YW, Cecka JM, Terasaki PI. HLA matching effect: better survival rates and graft quality. Clin Transpl. 1994;435–49.
Takamoto S, Terasaki PI, Cecka JM, Cho YW, Gjerston DW. Survival of nationally matched kidney transplants from cadaveric donors. N Engl J Med. 1992;327:834–9.
Terasaki PI, Cho Y, Takemoto S, Cecka M, Gjertson D. Twenty-year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival. Transplant Proc. 1996;28(3):1144–5.
Haas M, Montgomery RA, Segev DL, Rahman MH, Racusen LC, Bagnasco SM, Simpkins CE, Warren DS, Lepley D, Zachary AA, Kraus ES. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant. 2007;7(3):576–85.
Ozawa M, Terasaki PI, Lee JH, Castro R, Alberu J, Alonso C, Alvarez I, Toledo R, Alvez H, Monterio M, Teixeira J, Campbell P, Ciszek M, Charron D, Gautreau C, Christiansen F, Conca R, Gomez B, Monteon F, Grosse-Wilde H, Heinemann F, Humar I, Kamoun M, Kimball P, Kobayashi T, Kupatawintu P, Leech S, LeFor W, Mehra N, Panigrahi A, Naumova E, Norman D, Piazza A, Poli F, Colombo B, Roy R, Schonemann C, Sireci G, Tanabe K, Ishida H, Van den Berg-Loonen E, Zeevi A. 14th international HLA and immunogenetics workshop: report on the prospective chronic rejection project. Tissue Antigens. 2007;69 Suppl 1:174–9.
Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, Kupiec-Weglinski J, Matas A, Montgomery RA, Nickerson P, Platt JL, Rabb H, Thistlethwaite R, Tyan D, Delmonico FL. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4(7):1033.
Terasaki PI. Humoral theory of transplantation. Am J Transplant. 2003;3(6):665–73.
Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007;7(2):408–15.
SRTR. 2012 Annual data report. 2012.
Farney AC, Singh RP, Hines MH, Rogers J, Hartmann EL, Reeves-Daniel A, Gautreaux MD, Iskandar SS, Adams PL, Stratta RJ. Experience in renal and extrarenal transplantation with donation after cardiac death donors with selective use of extracorporeal support. J Am Coll Surg. 2008;206(5):1028–37. discussion 1037.
Locke JE, Segev DL, Warren DS, Dominici F, Simpkins CE, Montgomery RA. Outcomes of kidneys from donors after cardiac death: implications for allocation and preservation. Am J Transplant. 2007;7(7):1797–807.
Van Arendonk KJ, James NT, Locke JE, Montgomery RA, Colombani PM, Segev DL. Late graft loss among pediatric recipients of DCD kidneys. Clin J Am Soc Nephrol. 2011;6(11):2705–11.
Sumrani N, Delaney V, Ding ZK, Davis R, Daskalakis P, Tejani A, Butt K, Hong J. Renal transplantation from elderly living donors. Transplantation. 1991;51(2):305–9.
Salvatierra Jr O, Singh T, Shifrin R, Conley S, Alexander S, Tanney D, Lemley K, Sarwal M, Mackie F, Alfrey E, Orlandi P, Zarins C, Herfkens R. Successful transplantation of adult-sized kidneys into infants requires maintenance of high aortic blood flow. Transplantation. 1998;66(7):819–23.
Gregoir W. The surgical treatment of congenital vesico-ureteral reflux. Acta Chir Belg. 1964;63:431–9.
Politano VA, Leadbetter WF. An operative technique for the correction of vesicoureteral reflux. J Urol. 1958;79(6):932–41.
French CG, Acott PD, Crocker JF, Bitter-Suermann H, Lawen JG. Extravesical ureteroneocystostomy with and without internalized ureteric stents in pediatric renal transplantation. Pediatr Transplant. 2001;5(1):21–6.
Wacksman J, Gilbert A, Sheldon CA. Results of the renewed extravesical reimplant for surgical correction of vesicoureteral reflux. Journal of Urology. 1992;148(2 Pt 1):359–61.
Zaontz MR, Maizels M, Sugar EC, Firlit CF. Detrusorrhaphy: extravesical ureteral advancement to correct vesicoureteral reflux in children. Journal of Urology. 1987;138(4 Pt 2):947–9.
Dharnidharka VR, Araya CE, Wadsworth CS, McKinney MC, Howard RJ. Assessing the value of ureteral stent placement in pediatric kidney transplant recipients. Transplantation. 2008;85(7):986–91.
Fayek SA, Keenan J, Haririan A, Cooper M, Barth RN, Schweitzer E, Bromberg JS, Bartlett ST, Philosophe B. Ureteral stents are associated with reduced risk of ureteral complications after kidney transplantation: a large single center experience. Transplantation. 2012;93(3):304–8.
Mangus RS, Haag BW. Stented versus nonstented extravesical ureteroneocystostomy in renal transplantation: a metaanalysis. Am J Transplant. 2004;4(11):1889–96.
Wilson CH, Bhatti AA, Rix DA, Manas DM. Routine intraoperative stenting for renal transplant recipients. Transplantation. 2005;80(7):877–82.
Yarlagadda SG, Coca SG, Garg AX, Doshi M, Poggio E, Marcus RJ, Parikh CR. Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol Dial Transplant. 2008;23(9):2995–3003.
Benfield MR, Herrin J, Feld L, Rose S, Stablein D, Tejani A. Safety of kidney biopsy in pediatric transplantation: a report of the controlled clinical trials in pediatric transplantation trial of induction therapy study group. Transplantation. 1999;67(4):544–7.
Briscoe DM, Hoffer FA, Tu N, Harmon WE. Duplex Doppler examination of renal allografts in children: correlation between renal blood flow and clinical findings. Pediatr Radiol. 1993;23(5):365–8.
Aquino-Dias EC, Joelsons G, da Silva DM, Berdichevski RH, Ribeiro AR, Veronese FJ, Goncalves LF, Manfro RC. Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function. Kidney Int. 2008;73(7):877–84.
Gjertson DW. Impact of delayed graft function and acute rejection on kidney graft survival. Clin Transpl. 2000;467–80.
Tejani A, Sullivan EK, Alexander S, Fine R, Harmon W, Lilienfeld D. Posttransplant deaths and factors that influence the mortality rate in North American children. Transplantation. 1994;57(4):547–53.
Tejani A, Sullivan EK, Alexander SR, Fine RN, Harmon WE, Kohaut E. Predictive factors for acute tubular necrosis (ATN) and its impact on renal graft survival in children. 16th annual meeting of the American society of transplant physicians, Chicago, Abs. 1997.
Smith JM, McDonald RA, Stablein D, Singh A, Harmon WE. The impact of interleukin-2 receptor antibodies on renal allograft thrombosis: an analysis of the North American pediatric renal transplant cooperative study. Am J Transplant. 2003;3 Suppl 5:166.
Balachandra S, Tejani A. Recurrent vascular thrombosis in an adolescent transplant recipient. [Review]. J Am Soc Nephrol. 1997;8(9):1477–81.
Smith JM, Stablein D, Singh A, Harmon W, McDonald RA. Decreased risk of renal allograft thrombosis associated with interleukin-2 receptor antagonists: a report of the NAPRTCS. Am J Transplant. 2006;6(3):585–8.
Kim MS, Stablein D, Harmon WE. Renal transplantation in children with congenital nephrotic syndrome: a report of the North American pediatric renal transplant cooperative study (NAPRTCS). Pediatr Transplant. 1998;2(4):305–8.
Wheeler MA, Taylor CM, Williams M, Moghal N. Factor V Leiden: a risk factor for renal vein thrombosis in renal transplantation. Pediatr Nephrol. 2000;14(6):525–6.
Schurman SJ, Stablein DM, Perlman SA, Warady BA. Center volume effects in pediatric renal transplantation. A report of the North American pediatric renal transplant cooperative study. Pediatr Nephrol. 1999;13(5):373–8.
McDonald RA, Smith JM, Stablein D, Harmon WE. Pretransplant peritoneal dialysis and graft thrombosis following pediatric kidney transplantation: a NAPRTCS report. Pediatr Transplant. 2003;7(3):204–8.
Vats AN, Donaldson L, Fine RN, Chavers BM. Pretransplant dialysis status and outcome of renal transplantation in North American children: a NAPRTCS study. North American pediatric renal transplant cooperative study. Transplantation. 2000;69(7):1414–9.
Lundin C, Bersztel A, Wahlberg J, Wadstrom J. Low molecular weight heparin prophylaxis increases the incidence of lymphocele after kidney transplantation. Ups J Med Sci. 2002;107(1):9–15.
Suthanthiran M, Schwartz JE, Ding R, Abecassis M, Dadhania D, Samstein B, Knechtle SJ, Friedewald J, Becker YT, Sharma VK, Williams NM, Chang CS, Hoang C, Muthukumar T, August P, Keslar KS, Fairchild RL, Hricik DE, Heeger PS, Han L, Liu J, Riggs M, Ikle DN, Bridges ND, Shaked A, I. Clinical Trials in Organ Transplantation 04 Study. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013;369(1):20–31.
Vidhun J, Masciandro J, Varich L, Salvatierra Jr O, Sarwal M. Safety and risk stratification of percutaneous biopsies of adult-sized renal allografts in infant and older pediatric recipients. Transplantation. 2003;76(3):552–7.
Kaabak MM, Babenko NN, Samsonov DV, Sandrikov VA, Maschan AA, Zokoev AK. Alemtuzumab induction in pediatric kidney transplantation. Pediatr Transplant. 2013;17(2):168–78.
McDonald R, Smith J, Meyers K, Mathias R, Portale A, Ikle D, Morrison Y, Bridges N, Harmon W. A phase II exploratory study to evaluate the safety of induction therapy with campath-1H, combined with chronic immunosuppression with MMF and sirolimus: a study of the cooperative clinical trials in pediatric transplantation (Abs). Am J Transpl. 2008;8(s-2):192.
Ona ET, Danguilan RA, Africa J, Cabanayan-Casasola CB, Antonio ZL, Gutierrez-Marbella MA, dela Cruz R, Bumanglag N, Espedilla ME. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation. Transplant Proc. 2008;40(7):2226–9.
Shapiro R, Basu A, Tan H, Gray E, Kahn A, Randhawa P, Murase N, Zeevi A, Girnita A, Metes D, Ness R, Bass DC, Demetris AJ, Fung JJ, Marcos A, Starzl TE. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg. 2005;200(4):505.
Tan HP, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J, Unruh M, Randhawa P, Zeevi A, Shapiro R. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or campath and laparoscopy in living donor renal transplantation. Transplant Proc. 2005;37(10):4235.
Sarwal MM. Out with the old, in with the new: immunosuppression minimization in children. Curr Opin Organ Transplant. 2008;13(5):513–21.
Barletta GM, Kirk E, Gardner JJ, Rodriguez JF, Bursach SM, Bunchman TE. Rapid discontinuation of corticosteroids in pediatric renal transplantation. Pediatr Transplant. 2009;13(5):571–8.
Chavers BM, Chang YC, Gillingham KJ, Matas A. Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results. Transplantation. 2009;88(2):237–41.
Tan HP, Donaldson J, Ellis D, Moritz ML, Basu A, Morgan C, Vats AN, Erkan E, Shapiro R. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Transplantation. 2008;86(12):1725–31.
Benfield MR, Bartosh S, Ikle D, Warshaw B, Bridges N, Morrison Y, Harmon W. A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant. 2010;10(1):81–8.
Hocker B, Weber LT, Feneberg R, Drube J, John U, Fehrenbach H, Pohl M, Zimmering M, Frund S, Klaus G, Wuhl E, Tonshoff B. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. Transplantation. 2009;87(6):934–41.
Sarwal M, Benfield M, Ettenger R, Dharnidharka V, Mathias R, McDonald RA, Harmon W, Kershaw D, Vehaskari V, Kamil E, Baluarte H, Warady B, Ikle D, Bridges N, Salvatierra O. One year results of a prospective, randomized, multicenter trial of steroid avoidance in pediatric renal transplantation (Abs). Am J Transpl. 2008;8(s-2):192.
Hymes LC, Warshaw BL. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant. Pediatr Transplant. 2005;9(4):520–2.
McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, Wyatt R, Arar M, Liereman D, Bridges N, Harmon W, C. S. Group. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8(5):984–9.
Harmon W, Meyers K, Ingelfinger J, McDonald R, McIntosh M, Ho M, Spaneas L, Palmer JA, Hawk M, Geehan C, Tinckam K, Hancock WW, Sayegh MH. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. Journal Of The American Society Of Nephrology: JASN. 2006;17(6):1735–45.
Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant. 2004;4(3):384–9.
Wu K, Budde K, Lu H, Schmidt D, Liefeldt L, Glander P, Neumayer HH, Rudolph B. The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes. Transplantation. 2014;97(11):1146–54.
Opelz G, Dohler B, R. Collaborative Transplant Study. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation. 2008;85(5):661–6.
Mauiyyedi S, Crespo M, Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Tolkoff-Rubin NE, Williams WW, Delmonico FL, Cosimi AB, Colvin RB. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol. 2002;13(3):779–87.
Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753–60.
Mueller A, Schnuelle P, Waldherr R, van der Woude FJ. Impact of the Banff ’97 classification for histological diagnosis of rejection on clinical outcome and renal function parameters after kidney transplantation. Transplantation. 2000;69(6):1123–7.
Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation. 2006;81(7):953–65.
Mariat C, Alamartine E, Diab N, de Filippis JP, Laurent B, Berthoux F. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl Int. 1998;11(3):231–6.
Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, Light JA, Gaber LW, Squiers E, Taylor RJ, Neylan JF, Steiner RW, Knechtle S, Norman DJ, Shihab F, Basadonna G, Brennan DC, Hodge EE, Kahan BD, Kahan L, Steinberg S, Woodle ES, Chan L, Ham JM, Schroeder TJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998;66(1):29–37.
Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation. 2002;73(9):1514–8.
Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005;37(2):923–6.
Upadhyay K, Midgley L, Moudgil A. Safety and efficacy of alemtuzumab in the treatment of late acute renal allograft rejection. Pediatr Transplant. 2012;16(3):286–93.
Marks WH, Ilsley JN, Dharnidharka VR. Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. Transplant Proc. 2011;43(5):1395–404.
Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388–99.
Haas M. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol. 2011;75(4):271–8.
Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant. 2009;9(10):2312–23.
Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris 3rd AB, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M, c. Banff meeting report writing, Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272–83.
Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014;14(2):255–71.
Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94(8):775–83.
Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant. 2009;9(5):1099–107.
Bonomini V, Vangelista A, Frasca GM, Di Felice A, Liviano D’Arcangelo G. Effects of plasmapheresis in renal transplant rejection. A controlled study. Trans Am Soc Artif Intern Organs. 1985;31:698–703.
Allen NH, Dyer P, Geoghegan T, Harris K, Lee HA, Slapak M. Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation. 1983;35(5):425–8.
Blake P, Sutton D, Cardella CJ. Plasma exchange in acute renal transplant rejection. Prog Clin Biol Res. 1990;337:249–52.
Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004;4(6):996–1001.
Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, Ribes D, Cointault O, Lavayssiere L, Guitard J, Durand D, Rostaing L. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation. 2007;83(9):1277–80.
Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754–61.
Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9(1):231–5.
Chehade H, Rotman S, Matter M, Girardin E, Aubert V, Pascual M. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. Pediatrics. 2015;135(2):e551–5.
Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation. 2014;98(8):857–63.
Kidney Disease: Improving Global Outcomes Transplant Work, G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1–155.
Jordan SC, Reinsmoen N, Peng A, Lai CH, Cao K, Villicana R, Toyoda M, Kahwaji J, Vo AA. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol. 2010;25(10):2035–45. quiz 2045–2038.
Tilney NL. Early course of a patient. In: Morris PJ, editor. Kidney transplantation: principles and practice. Philadelphia: WB Saunders; 1988. p. 278–83.
Chapman JR, O’Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005;16(10):3015–26.
Fellstrom B, Holdaas H, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Staffler B, Pedersen TR, I. Assessment of Lescol in Renal Transplantation Study. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation. 2005;79(2):205–12.
Kasiske BL, Kalil RS, Lee HS, Rao KV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int. 1991;40(3):514–24.
Monaco AP, Burke Jr JF, Ferguson RM, Halloran PF, Kahan BD, Light JA, Matas AJ, Solez K. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis. 1999;33(1):150–60.
Regele H, Bohmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S, Watschinger B, Kerjaschki D, Exner M. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol. 2002;13(9):2371–80.
Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ. Banff ’05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant. 2007;7(3):518–26.
Gough J, Yilmaz A, Miskulin D, Gedeon I, Burama A, Yilmaz S, Supanj F, Muruve D, McKenna R, Benediktsson H. Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens. Transplantation. 2001;71(10):1390–3.
Seron D, Moreso F, Ramon JM, Hueso M, Condom E, Fulladosa X, Bover J, Gil-Vernet S, Castelao AM, Alsina J, Grinyo JM. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation. 2000;69(9):1849–55.
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326–33.
Carpenter CB. Long-term failure of renal transplants: adding insult to injury. Kidney Int Suppl. 1995;50:S40–4.
Opelz G, S. Collaborative Transplant. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet. 2005;365(9470):1570–6.
Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation. 1994;57(6):857–9.
Guyot C, Nguyen JM, Cochat P, Foulard M, Bouissou F, Van Damme-Lombaerts R, Loirat C, Janssen F, Bensman A, Nivet H, Fischbach M, Guignard JP, Andre JL. Risk factors for chronic rejection in pediatric renal allograft recipients. Pediatr Nephrol. 1996;10(6):723–7.
Humar A, Payne WD, Sutherland DE, Matas AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation. 2000;69(11):2357–60.
Tejani A, Cortes L, Stablein D. Clinical correlates of chronic rejection in pediatric renal transplantation. A report of the North American pediatric renal transplant cooperative study. Transplantation. 1996;61(7):1054–8.
Bia MJ. Nonimmunologic causes of late renal graft loss. Kidney Int. 1995;47(5):1470–80.
Dart AB, Schall A, Gibson IW, Blydt-Hansen TD, Birk PE. Patterns of chronic injury in pediatric renal allografts. Transplantation. 2010;89(3):334–40.
Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol. 2011;22(11):2107–18.
Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, Garcia VD, Kamar N, Lang P, Manfro RC, Massari P, Rial MD, Schnitzler MA, Vitko S, Duan T, Block A, Harler MB, Durrbach A. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12(3):630–9.
Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004;4(11):1869–75.
Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CTSG. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2):233–42.
Merville P, Berge F, Deminiere C, Morel D, Chong G, Durand D, Rostaing L, Mourad G, Potaux L. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant. 2004;4(11):1769–75.
Sarwal MM, Ettenger RB, Dharnidharka V, Benfield M, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Tang L, Liu J, Li L, Naesens M, Sigdel T, Waskerwitz J, Salvatierra O. Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant. 2012;12(10):2719–29.
Li L, Chang A, Naesens M, Kambham N, Waskerwitz J, Martin J, Wong C, Alexander S, Grimm P, Concepcion W, Salvatierra O, Sarwal MM. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant. 2009;9(6):1362–72.
Mitsnefes MM. Hypertension and end-organ damage in pediatric renal transplantation. Pediatr Transplant. 2004;8(4):394–9.
Seeman T. Management of proteinuria in the transplanted patient. Pediatr Nephrol. 2015;30(6):889–903.
Group, E. T., Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Moller K, Wigger M, Peruzzi L, Mehls O, Schaefer F. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639–50.
Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347(2):103–9.
Fine RN. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol. 2007;22(4):496–502.
Nehus EJ, Goebel JW, Succop PS, Abraham EC. Focal segmental glomerulosclerosis in children: multivariate analysis indicates that donor type does not alter recurrence risk. Transplantation. 2013;96(6):550–4.
Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med. 1992;92(4):375–83.
Dantal J, Baatard R, Hourmant M, Cantarovich D, Buzelin F, Soulillou JP. Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects. Transplantation. 1991;52(5):827–31.
Abbott KC, Sawyers ES, Oliver 3rd JD, Ko CW, Kirk AD, Welch PG, Peters TG, Agodoa LY. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis. 2001;37(2):366–73.
Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American pediatric renal transplant cooperative study. J Am Soc Nephrol. 1992;2 Suppl 12:S258–63.
Pollak MR. Familial FSGS. Adv Chronic Kidney Dis. 2014;21(5):422–5.
Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis. Semin Nephrol. 2003;23(2):141–6.
Becker-Cohen R, Bruschi M, Rinat C, Feinstein S, Zennaro C, Ghiggeri GM, Frishberg Y. Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies. Am J Transplant. 2007;7(1):256–60.
Billing H, Muller D, Ruf R, Lichtenberger A, Hildebrandt F, August C, Querfeld U, Haffner D. NPHS2 mutation associated with recurrence of proteinuria after transplantation. Pediatr Nephrol. 2004;19(5):561–4.
Weber S, Tonshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation. 2005;80 Suppl 1:S128–34.
Bertelli R, Ginevri F, Caridi G, Dagnino M, Sandrini S, Di Duca M, Emma F, Sanna-Cherchi S, Scolari F, Neri TM, Murer L, Massella L, Basile G, Rizzoni G, Perfumo F, Ghiggeri GM. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis. 2003;41(6):1314–21.
Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med. 2006;354(18):1961–3.
Sahali D, Pawlak A, Valanciute A, Grimbert P, Lang P, Remy P, Bensman A, Guellaen G. A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol. 2002;13(5):1238–47.
Gohh RY, Yango AF, Morrissey PE, Monaco AP, Gautam A, Sharma M, McCarthy ET, Savin VJ. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant. 2005;5(12):2907–12.
Gonzalez E, Ettenger R, Rianthavorn P, Tsai E, Malekzadeh M. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant. 2011;15(5):495–501.
Ohta T, Kawaguchi H, Hattori M, Komatsu Y, Akioka Y, Nagata M, Shiraga H, Ito K, Takahashi K, Ishikawa N, Tanabe K, Yamaguchi Y, Ota K. Effect of pre-and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation. 2001;71(5):628–33.
Audard V, Kamar N, Sahali D, Cardeau-Desangles I, Homs S, Remy P, Aouizerate J, Matignon M, Rostaing L, Lang P, Grimbert P. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl Int. 2012;25(5):e62–6.
Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke 3rd GW. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46.
Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation. 2013;96(7):649–56.
Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis. 1994;23(4):574–81.
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–60.
Cheong HI, Han HW, Park HW, Ha IS, Han KS, Lee HS, Kim SJ, Choi Y. Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2000;15(1):78–81.
Dall’Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Zamorani E, Zennaro C, Basile G, Montini G, Rivabella L, Cardillo M, Scalamogna M, Ginevri F. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis. 1999;34(6):1048–55.
Canaud G, Zuber J, Sberro R, Royale V, Anglicheau D, Snanoudj R, Gaha K, Thervet E, Lefrere F, Cavazzana-Calvo M, Noel LH, Mejean A, Legendre C, Martinez F. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant. 2009;9(5):1081–6.
Nathanson S, Cochat P, Andre JL, Guyot C, Loirat C, Nivet H, Deschenes G. Recurrence of nephrotic syndrome after renal transplantation: influence of increased immunosuppression. Pediatr Nephrol. 2005;20(12):1801–4.
Shishido S, Satou H, Muramatsu M, Hamasaki Y, Ishikura K, Hataya H, Honda M, Asanuma H, Aikawa A. Combination of pulse methylprednisolone infusions with cyclosporine-based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Clin Transplant. 2013;27(2):E143–50.
Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke 3rd GW, Mundel P. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369(25):2416–23.
Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol. 2015;30(3):469–77.
Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365(9464):1073–86.
Spinale JM, Ruebner RL, Kaplan BS, Copelovitch L. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr. 2013;25(2):203–8.
Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol. 2003;18(11):1095–101.
Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554–62.
Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676–87.
Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, R. International Registry of and H. T. Familial. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–79.
Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, N. French Society of Pediatric. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392–400.
Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7(1):23–35.
Miriuka SG, Rao V, Peterson M, Tumiati L, Delgado DH, Mohan R, Ramzy D, Stewart D, Ross HJ, Waddell TK. mTOR inhibition induces endothelial progenitor cell death. Am J Transplant. 2006;6(9):2069–79.
Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508.
Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Fremeaux-Bacchi V. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663–75.
Fortin MC, Raymond MA, Madore F, Fugere JA, Paquet M, St-Louis G, Hebert MJ. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant. 2004;4(6):946–52.
Lovric S, Kielstein JT, Kayser D, Brocker V, Becker JU, Hiss M, Schiffer M, Sommerwerck U, Haller H, Struber M, Welte T, Gottlieb J. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients – a case series. Nephrol Dial Transplant. 2011;26(9):3032–8.
Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–59.
Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noel LH, Hourmant M, Niaudet P, Fremeaux-Bacchi V, Rondeau E, Legendre C, Loirat C, H. U. S. French Study Group for Atypical. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337–54.
Goh BK, Chedid MF, Gloor JM, Raghavaiah S, Stegall MD. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts. Transpl Immunol. 2012;27(2–3):95–100.
Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64(4):633–7.
Cheong HI, Lee BS, Kang HG, Hahn H, Suh KS, Ha IS, Choi Y. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol. 2004;19(4):454–8.
Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G, Gridelli B. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet. 2002;359(9318):1671–2.
Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P, Bucchioni S, Sonzogni A, Bonanomi E, Sonzogni V, Platt JL, Perico N, Noris M. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant. 2005;5(5):1146–50.
Saland J. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr Nephrol. 2014;29(3):329–32.
Pickering MC, D’Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fremeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodriguez de Cordoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079–89.
Lien YH, Scott K. Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. Am J Kidney Dis. 2000;35(3):539–43.
Muczynski KA. Plasmapheresis maintained renal function in an allograft with recurrent membranoproliferative glomerulonephritis type I. Am J Nephrol. 1995;15(5):446–9.
Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012;82(4):465–73.
Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, Katz LM, Sethi S, Smith RJ. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol. 2012;7(2):265–74.
Plumb TJ, Swee ML, Fillaus JA. Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria. Am J Kidney Dis. 2013;62(6):1155–9.
Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 2006;70(9):1642–8.
Broyer M, Brunner FP, Brynger H, Dykes SR, Ehrich JH, Fassbinder W, Geerlings W, Rizzoni G, Selwood NH, Tufveson G, et al. Kidney transplantation in primary oxalosis: data from the EDTA Registry. Nephrol Dial Transplant. 1990;5(5):332–6.
Muller T, Sikora P, Offner G, Hoyer PF, Brodehl J. Recurrence of renal disease after kidney transplantation in children: 24 years of experience in a single center. Clin Nephrol. 1998;49(2):82–90.
Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant. 2014;14(6):1433–8.
Ellis SR, Hulton SA, McKiernan PJ, de Ville de Goyet J, Kelly DA. Combined liver-kidney transplantation for primary hyperoxaluria type 1 in young children. Nephrol Dial Transplant. 2001;16(2):348–54.
Mizusawa Y, Parnham AP, Falk MC, Burke JR, Nicol D, Yamanaka J, Lynch SV, Strong RW. Potential for bilateral nephrectomy to reduce oxalate release after combined liver and kidney transplantation for primary hyperoxaluria type 1. Clin Transplant. 1997;11(5 Pt 1):361–5.
Van Arendonk KJ, Boyarsky BJ, Orandi BJ, James NT, Smith JM, Colombani PM, Segev DL. National trends over 25 years in pediatric kidney transplant outcomes. Pediatrics. 2014;133(4):594–601.
Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De Geest S. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant. 2005;9(3):381–90.
Patzer RE, Mohan S, Kutner N, McClellan WM, Amaral S. Racial and ethnic disparities in pediatric renal allograft survival in the United States. Kidney Int. 2015;87(3):584–92.
Powell DR, Liu F, Baker BK, Hinzt RL, Kale A, Suwanichkul A, Durham SK. Effect of chronic renal failure and growth hormone therapy on the insulin-like growth factors and their binding proteins. Pediatr Nephrol. 2000;14(7):579–83.
Rodig NM, McDermott KC, Schneider MF, Hotchkiss HM, Yadin O, Seikaly MG, Furth SL, Warady BA. Growth in children with chronic kidney disease: a report from the chronic kidney disease in children study. Pediatr Nephrol. 2014;29(10):1987–95.
Furth SL, Alexander DC, Neu AM, Hwang W, Powe NR, Fivush BA. Does growth retardation indicate suboptimal clinical care in children with chronic renal disease and those undergoing dialysis? Semin Nephrol. 2001;21(5):463–9.
Gerson AC, Wentz A, Abraham AG, Mendley SR, Hooper SR, Butler RW, Gipson DS, Lande MB, Shinnar S, Moxey-Mims MM, Warady BA, Furth SL. Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics. 2010;125(2):e349–57.
Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T, Sherrard DJ, Watkins SL, Stehman-Breen C. Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis. 2000;36(4):811–9.
Abitbol CL, Zilleruelo G, Montane B, Strauss J. Growth of uremic infants on forced feeding regimens. Pediatr Nephrol. 1993;7(2):173–7.
Seikaly MG, Salhab N, Gipson D, Yiu V, Stablein D. Stature in children with chronic kidney disease: analysis of NAPRTCS database. Pediatr Nephrol. 2006;21(6):793–9.
Tejani A, Fine R, Alexander S, Harmon W, Stablein D. Factors predictive of sustained growth in children after renal transplantation. The North American pediatric renal transplant cooperative study. J Pediatr. 1993;122(3):397–402.
Travis LB, Chesney R, McEnery P, Moel D, Pennisi A, Potter D, Talwalkar YB, Wolff E. Growth and glucocorticoids in children with kidney disease. Kidney Int. 1978;14(4):365–8.
Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr. 1992;120(5):721–5.
Jabs K, Sullivan EK, Avner ED, Harmon WE. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American pediatric renal transplant cooperative study. Transplantation. 1996;61(1):31–6.
Wittenhagen P, Thiesson HC, Baudier F, Pedersen EB, Neland M. Long-term experience of steroid-free pediatric renal transplantation: effects on graft function, body mass index, and longitudinal growth. Pediatr Transplant. 2014;18(1):35–41.
Mahan JD, Warady BA, Consensus C. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol. 2006;21(7):917–30.
Fine RN, Stablein D, Cohen AH, Tejani A, Kohaut E. Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS. Kidney Int. 2002;62(2):688–96.
Gil S, Vaiani E, Guercio G, Ciaccio M, Turconi A, Delgado N, Rivarola MA, Belgorosky A. Effectiveness of rhGH treatment on final height of renal-transplant recipients in childhood. Pediatr Nephrol. 2012;27(6):1005–9.
Kim JJ, Marks SD. Long-term outcomes of children after solid organ transplantation. Clinics (Sao Paulo). 2014;69 Suppl 1:28–38.
Tong A, Tjaden L, Howard K, Wong G, Morton R, Craig JC. Quality of life of adolescent kidney transplant recipients. J Pediatr. 2011;159(4):670–5.e672.
Apajasalo M, Rautonen J, Sintonen H, Holmberg C. Health-related quality of life after organ transplantation in childhood. Pediatr Transplant. 1997;1:130–7.
Kim MS, Jabs K, Harmon WE. Long-term patient survival in a pediatric renal transplantation program. Transplantation. 1991;51(2):413–6.
Morel P, Almond PS, Matas AJ, Gillingham KJ, Chau C, Brown A, Kashtan CE, Mauer SM, Chavers B, Nevins TE, et al. Long-term quality of life after kidney transplantation in childhood. Transplantation. 1991;52(1):47–53.
Potter DE, Najarian J, Belzer F, Holliday MA, Horns G, Salvatierra Jr O. Long-term results of renal transplantation in children. Kidney Int. 1991;40(4):752–6.
Haavisto A, Korkman M, Sintonen H, Holmberg C, Jalanko H, Lipsanen J, Qvist E. Risk factors for impaired quality of life and psychosocial adjustment after pediatric heart, kidney, and liver transplantation. Pediatr Transplant. 2013;17(3):256–65.
Tozzi AE, Mazzotti E, Di Ciommo VM, Dello Strologo L, Cuttini M. Quality of life in a cohort of patients diagnosed with renal failure in childhood and who received renal transplant. Pediatr Transplant. 2012;16(8):840–5.
Ehrich JH, Rizzoni G, Broyer M, Brunner FP, Brynger H, Fassbinder W, Geerlings W, Selwood NH, Tufveson G, Wing AJ. Rehabilitation of young adults during renal replacement therapy in Europe. 2. Schooling, employment, and social situation. Nephrol Dial Transplant. 1992;7(7):579–86.
Fine RN, Becker Y, De Geest S, Eisen H, Ettenger R, Evans R, Rudow DL, McKay D, Neu A, Nevins T, Reyes J, Wray J, Dobbels F. Nonadherence consensus conference summary report. Am J Transplant. 2009;9(1):35–41.
Meyers KE, Weiland H, Thomson PD. Paediatric renal transplantation non-compliance. Pediatr Nephrol. 1995;9(2):189–92.
Beck DE, Fennell RS, Yost RL, Robinson JD, Geary D, Richards GA. Evaluation of an educational program on compliance with medication regimens in pediatric patients with renal transplants. J Pediatr. 1980;96(6):1094–7.
Ettenger RB, Rosenthal JT, Marik JL, Malekzadeh M, Forsythe SB, Kamil ES, Salusky IB, Fine RN. Improved cadaveric renal transplant outcome in children. Pediatr Nephrol. 1991;5(1):137–42.
Bell F. Post-renal transplant compliance. J Child Health Care. 2000;4(1):5–9.
Foulkes LM, Boggs SR, Fennell RS, Skibinski K. Social support, family variables, and compliance in renal transplant children. Pediatr Nephrol. 1993;7(2):185–8.
Blowey DL, Hebert D, Arbus GS, Pool R, Korus M, Koren G. Compliance with cyclosporine in adolescent renal transplant recipients. Pediatr Nephrol. 1997;11(5):547–51.
Fennell RS, Foulkes LM, Boggs SR. Family-based program to promote medication compliance in renal transplant children. Transplant Proc. 1994;26(1):102–3.
Traum AZ, Ko DS, Kawai T. The potential for tolerance in pediatric renal transplantation. Curr Opin Organ Transplant. 2008;13(5):489–94.
Smith JM, Martz K, McDonald RA, Harmon WE. Solid tumors following kidney transplantation in children. Pediatr Transplant. 2013;17(8):726–30.
Hooper SR, Gerson AC, Butler RW, Gipson DS, Mendley SR, Lande MB, Shinnar S, Wentz A, Matheson M, Cox C, Furth SL, Warady BA. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(8):1824–30.
Mendley SR, Matheson MB, Shinnar S, Lande MB, Gerson AC, Butler RW, Warady BA, Furth SL, Hooper SR. Duration of chronic kidney disease reduces attention and executive function in pediatric patients. Kidney Int. 2015;87(4):800–6.
Foster BJ, Dahhou M, Zhang X, Platt RW, Samuel SM, Hanley JA. Association between age and graft failure rates in young kidney transplant recipients. Transplantation. 2011;92(11):1237–43.
Van Arendonk KJ, James NT, Boyarsky BJ, Garonzik-Wang JM, Orandi BJ, Magee JC, Smith JM, Colombani PM, Segev DL. Age at graft loss after pediatric kidney transplantation: exploring the high-risk age window. Clin J Am Soc Nephrol. 2013;8(6):1019–26.
Andreoni KA, Forbes R, Andreoni RM, Phillips G, Stewart H, Ferris M. Age-related kidney transplant outcomes: health disparities amplified in adolescence. JAMA Intern Med. 2013;173(16):1524–32.
Keith DS, Cantarovich M, Paraskevas S, Tchervenkov J. Recipient age and risk of chronic allograft nephropathy in primary deceased donor kidney transplant. Transpl Int. 2006;19(8):649–56.
Smith JM, Ho PL, McDonald RA, S. North American Pediatric Renal Transplant Cooperative. Renal transplant outcomes in adolescents: a report of the North American pediatric renal transplant cooperative study. Pediatr Transplant. 2002;6(6):493–9.
Dew MA, Dabbs AD, Myaskovsky L, Shyu S, Shellmer DA, DiMartini AF, Steel J, Unruh M, Switzer GE, Shapiro R, Greenhouse JB. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation. 2009;88(5):736–46.
Pinsky BW, Takemoto SK, Lentine KL, Burroughs TE, Schnitzler MA, Salvalaggio PR. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant. 2009;9(11):2597–606.
Foster BJ. Heightened graft failure risk during emerging adulthood and transition to adult care. Pediatr Nephrol. 2015;30(4):567–76.
Watson AR, Harden P, Ferris M, Kerr PG, Mahan J, Ramzy MF. Transition from pediatric to adult renal services: a consensus statement by the international society of nephrology (ISN) and the international pediatric nephrology association (IPNA). Pediatr Nephrol. 2011;26(10):1753–7.
Bell LE, Bartosh SM, Davis CL, Dobbels F, Al-Uzri A, Lotstein D, Reiss J, Dharnidharka VR. Adolescent transition to adult care in solid organ transplantation: a consensus conference report. Am J Transplant. 2008;8(11):2230–42.
Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003;3(6):653–64.
Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D, Kamil E, Tyan D. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003;76(4):631–6.
Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, Toto RD, Wang X, Wright Jr JT, Greene TH. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012;59(4):504–12.
Li L, Khatri P, Sigdel TK, Tran T, Ying L, Vitalone MJ, Chen A, Hsieh S, Dai H, Zhang M, Naesens M, Zarkhin V, Sansanwal P, Chen R, Mindrinos M, Xiao W, Benfield M, Ettenger RB, Dharnidharka V, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Davis R, Butte AJ, Salvatierra O, Sarwal MM. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant. 2012;12(10):2710–8.
Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F, G. Arbeitsgemeinschaft Fur Padiatrische Nephrologie Study. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol. 2004;15(3):722–32.
Ruf RG, Schultheiss M, Lichtenberger A, Karle SM, Zalewski I, Mucha B, Everding AS, Neuhaus T, Patzer L, Plank C, Haas JP, Ozaltin F, Imm A, Fuchshuber A, Bakkaloglu A, Hildebrandt F, A. P. N. S. Group. Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int. 2004;66(2):564–70.
Dobbels F, Ruppar T, De Geest S, Decorte A, Van Damme-Lombaerts R, Fine RN. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatric transplantation 2010;14:603–13.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Rodig, N.M., Vakili, K., Harmon, W.E. (2015). Pediatric Renal Transplantation. In: Avner, E., Harmon, W., Niaudet, P., Yoshikawa, N., Emma, F., Goldstein, S. (eds) Pediatric Nephrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27843-3_65-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-27843-3_65-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27843-3
eBook Packages: Springer Reference MedicineReference Module Medicine